CapsoVision vs Neuraxis
CV and NRXS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CV and NRXS compare
CapsoVision is the larger company, worth 4.3 times as much as Neuraxis ($314M against $72.2M).
CapsoVision scores higher on the StockData Score (6 against 0 for Neuraxis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CV | NRXS |
|---|---|---|
| Size and price | ||
| Market cap | $314M | $72.2M |
| Share price | $6.27 | $5.75 |
| Change, 1 year | 15.2% | 139% |
| Beta (5Y) | −1.09 | 0.91 |
| Employees | 99 | 24 |
| StockData Score | ||
| Total score | 6 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 22.5× | – |
| P/B | 11.9× | – |
| FCF yield | −9.3% | – |
| Fair value | $1.28 | – |
| Margin of safety | −391% | – |
| Growth | ||
| Revenue growth (TTM) | 6.4% | – |
| Profitability | ||
| Gross margin | 49.7% | – |
| Operating margin | −212% | – |
| Net margin | −210% | – |
| FCF margin | −210% | – |
| Return on equity | −125% | – |
| Return on invested capital | −99.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 5.07 | – |
| Altman Z-score | 20.27 | – |
| Piotroski F-score | 3 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 10.2% | 21.7% |
| Held by insiders | 29.0% | 39.9% |
| Insider net buying, 12 months | $21.0M (better) | $1.4M |
| Short interest, % of float | 5.5% | 6.0% |
Go deeper
- CV stock overview
- CV income statement
- CV valuation and score
- NRXS stock overview
- NRXS income statement
- NRXS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.